AbbVie Inc. $ABBV is Ferguson Wellman Capital Management Inc.’s 7th Largest Position

Ferguson Wellman Capital Management Inc. boosted its position in AbbVie Inc. (NYSE:ABBV) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 647,685 shares of the company’s stock after purchasing an additional 3,260 shares during the quarter. AbbVie comprises approximately 2.4% of Ferguson Wellman Capital Management Inc.’s investment portfolio, making the stock its 7th largest position. Ferguson Wellman Capital Management Inc.’s holdings in AbbVie were worth $149,965,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the second quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. grew its position in shares of AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline/clinical progress — AbbVie advanced its icalcaprant (depression) Phase 2 program, which supports medium‑term pipeline optionality beyond its core immunology/oncology franchises. AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch
• Positive Sentiment: Early‑stage oncology expansion — AbbVie launched a first‑in‑human trial for ABBV‑901 in ovarian cancer, increasing optional upside if the program shows early signal. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Positive Sentiment: Analyst support — Berenberg issued a buy on ABBV, giving some near‑term credibility to upside narratives and providing a buy signal for income/value investors. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Dividend/income appeal — commentary highlighting AbbVie’s yield and steady dividend profile is keeping income‑focused investors engaged despite valuation premium. AbbVie: The Dividend Does Not Lie
• Neutral Sentiment: Real‑world study readouts — post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped, which may gradually support label expansion and payer confidence but are not immediate revenue catalysts. AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data
• Neutral Sentiment: Upcoming results call — AbbVie set its full‑year and Q4 earnings release and Feb. 4 conference call; investors will watch guidance reconciliation and quarterly details for clarity. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Negative Sentiment: Guidance slightly below consensus — AbbVie trimmed/updated Q4 and FY‑2025 EPS ranges that sit at or just below street consensus, which likely pressured the stock as investors reprice near‑term growth expectations.
• Negative Sentiment: One‑time IPR&D/R&D charges — management flagged IPR&D and related expenses that will negatively impact Q4 EPS, creating near‑term earnings noise ahead of the February print. AbbVie sees negative Q4 EPS impact from IPR&D expenses
• Negative Sentiment: Failed takeover optimism — earlier media reports that AbbVie was in talks to buy Revolution Medicines briefly lifted sentiment; AbbVie subsequently denied talks, prompting disappointment and a reversal in momentum. AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

Analysts Set New Price Targets

A number of brokerages recently commented on ABBV. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Bank of America lifted their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Price Performance

Shares of ABBV stock opened at $224.22 on Friday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a market cap of $396.28 billion, a PE ratio of 169.86, a price-to-earnings-growth ratio of 0.98 and a beta of 0.36. The company has a 50-day moving average of $226.55 and a two-hundred day moving average of $214.86.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.